tetano
Editor, Senior Moderator
Osong Public Health Res Perspect
. 2022 Jun;13(3):184-190.
doi: 10.24171/j.phrp.2022.0014. Epub 2022 Jun 10.
Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis
Pragya Sharma[SUP] 1 [/SUP], Saurav Basu[SUP] 2 [/SUP], Suruchi Mishra[SUP] 1 [/SUP], Mongjam Meghachandra Singh[SUP] 1 [/SUP]
Affiliations
Abstract
Objectives: The aim of this study was to assess changes in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) seroprevalence among children and adolescents in Delhi, India from January 2021 to October 2021.
Methods: This was a repeated cross-sectional analysis of participants aged 5 to 17 years from 2 SARS-CoV-2 seroprevalence surveys conducted in Delhi, India during January 2021 and September to October 2021. Anti-SARS-CoV-2 IgG antibodies were detected by using the VITROS assay (90% sensitivity, 100% specificity).
Results: The seroprevalence among 5- to 17-year-old school-age children and adolescents increased from 52.8% (95% confidence interval [CI], 51.3%-54.3%) in January 2021 to 81.8% (95% CI, 80.9%-82.6%) in September to October 2021. The assay-adjusted seroprevalence was 90.8% (95% CI, 89.8%-91.7%). Seropositivity positively correlated with participants' age (p<0.001), but not sex (p=0.388). A signal to cut-off ratio ≥4.00, correlating with the presence of neutralization antibodies, was observed in 4,814 (57.9%) participants.
Conclusion: The high percentage of seroconversion among children and adolescents indicates the presence of natural infection-induced immunity from past exposure to the SARS-CoV-2 virus. However, the lack of hybrid immunity and the concomitant likelihood of lower levels of neutralization antibodies than in adults due to the absence of vaccination warrants careful monitoring and surveillance of infection risk and disease severity from newer and emergent variants.
Keywords: COVID-19; India; Infection; SARS-CoV-2.
. 2022 Jun;13(3):184-190.
doi: 10.24171/j.phrp.2022.0014. Epub 2022 Jun 10.
Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis
Pragya Sharma[SUP] 1 [/SUP], Saurav Basu[SUP] 2 [/SUP], Suruchi Mishra[SUP] 1 [/SUP], Mongjam Meghachandra Singh[SUP] 1 [/SUP]
Affiliations
- PMID: 35820667
- DOI: 10.24171/j.phrp.2022.0014
Abstract
Objectives: The aim of this study was to assess changes in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) seroprevalence among children and adolescents in Delhi, India from January 2021 to October 2021.
Methods: This was a repeated cross-sectional analysis of participants aged 5 to 17 years from 2 SARS-CoV-2 seroprevalence surveys conducted in Delhi, India during January 2021 and September to October 2021. Anti-SARS-CoV-2 IgG antibodies were detected by using the VITROS assay (90% sensitivity, 100% specificity).
Results: The seroprevalence among 5- to 17-year-old school-age children and adolescents increased from 52.8% (95% confidence interval [CI], 51.3%-54.3%) in January 2021 to 81.8% (95% CI, 80.9%-82.6%) in September to October 2021. The assay-adjusted seroprevalence was 90.8% (95% CI, 89.8%-91.7%). Seropositivity positively correlated with participants' age (p<0.001), but not sex (p=0.388). A signal to cut-off ratio ≥4.00, correlating with the presence of neutralization antibodies, was observed in 4,814 (57.9%) participants.
Conclusion: The high percentage of seroconversion among children and adolescents indicates the presence of natural infection-induced immunity from past exposure to the SARS-CoV-2 virus. However, the lack of hybrid immunity and the concomitant likelihood of lower levels of neutralization antibodies than in adults due to the absence of vaccination warrants careful monitoring and surveillance of infection risk and disease severity from newer and emergent variants.
Keywords: COVID-19; India; Infection; SARS-CoV-2.